Value of Syntara, page-2

  1. 912 Posts.
    lightbulb Created with Sketch. 577
    A buyout is premature.

    I'm more concerned about possible licensing deals being thrown in disarray. Not knowing the pricing and potential market size is going to throw a massive spanner. Any possible deals might be on the backburner for the next few months

    2 of our big possible suitors are throwing big cash at US investment and now some companies are second guessing that investment. I would think all big pharma would be looking very closely at their financials.

    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-invest-40-billion-us-over-5-years-ceo-says-2025-05-05/
    https://www.fiercepharma.com/manufacturing/following-lilly-and-jj-novartis-unveils-23b-investment-beef-us-manufacturing-rd
    https://firstwordpharma.com/story/5959828

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.5¢
Change
-0.012(17.9%)
Mkt cap ! $89.35M
Open High Low Value Volume
6.7¢ 6.7¢ 5.5¢ $557.8K 9.456M

Buyers (Bids)

No. Vol. Price($)
1 8258 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.2¢ 26672 4
View Market Depth
Last trade - 15.59pm 16/06/2025 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.